Shennon Biotechnologies
CA - San FranciscoBiotechnology
Focus: Shennon Biotechnologies is a pre-revenue biotech company developing a proprietary single-cell platform to create more effective immunotherapies in oncology and neurology. The company is early-stage and recently secured $12M in funding with new leadership to advance its pipeline.
Profile data last refreshed 5h ago · AI intelligence enriched 3w ago
Open Jobs
6+2 this month
Stable — net +2 jobs in 30d
2 added, 0 removed. Backfill posture.
Should You Work at Shennon Biotechnologies?
AI assessmentBest fit for early-career scientists seeking platform-building opportunity at a well-capitalized early-stage biotech, with elevated risk typical of pre-revenue companies.
Why Work Here
- Join a newly funded platform company with fresh capital ($12M raised September 2026) and a newly appointed CEO (Cyril Konto, M.D., ex-Novartis) to establish early-stage infrastructure.
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Shennon Biotechnologies
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.